The Future in Heart Failure: Novel Therapies, Innovative Trial Designs & Stakeholder Diversity

Dr. Murphy’s professional career has spanned over 25 years in positions within the pharmaceutical industry. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University and the Mt. Sinai School of Medicine. His contributions as Chief Medical & Scientific Officer at Worldwide encompass all therapeutic areas under Worldwide’s umbrella, and include translational research activities, scientific regulatory support, and protocol development for phases I–IV. He has been a consultant for the Duke Clinical Research Institute and is Founder and Research & Development Editor for American Health and Drug Benefits™. As a lecturer within the Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology (HST) for 17 years, Dr. Murphy contributed to the curriculum for a two-year Clinical Investigator Training Program.

Toni spent 10 years in academia as a clinical cardiologist at St. Louis University followed by University of Minnesota. Her subspecialty being cardiac imaging, she spent several years performing industry sponsored research in ultrasound microbubble imaging at St. Louis University and investigator-initiated research at University of Minnesota. She was a fixture in the cardiology clinics as well and was noted as one of the top cardiologists in St. Louis in 2000. In 2006 she left academics to work in the pharmaceutical industry, primarily big pharma where she has worked for 10 years (Schering Plough, Novartis). She has worked for Worldwide Clinical Trials since August, 2015 in the cardiovascular therapeutic area as a medical monitor.

Dr. Murphy’s professional career has spanned 25 years and his positions within the pharmaceutical industry emphasize the integration of medical and scientific acumen with operational excellence. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University and the Mt. Sinai School of Medicine. His supervisory responsibilities as Chief Medical & Scientific Officer at Worldwide Clinical Trials are international in scope and include strategic program and protocol design contributions for translational research activities, particularly for orphan disease indications. He is Research & Development Editor for American Health & Drug Benefits™ a publication which focuses upon cost, quality and access in the transition of novel diagnostics and therapeutics from discovery to commercialization. As is lecturer within the Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology (HST) for 17 years, he contributed to the curriculum for a two-year Clinical Investigator Training Program for physicians seeking advanced credentialing in experimental medicine and protocol design. He is an contributor to the Harvard Catalyst lecture series supporting the Clinical and Translational Science Center.

x